Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pulmatrix Inc    PULM

PULMATRIX INC (PULM)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsCalendarCompany 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/17/2017 11/20/2017 11/21/2017 11/22/2017 11/24/2017 Date
1.62(c) 1.63(c) 1.57(c) 1.62(c) 1.63(c) Last
71 719 88 772 114 355 84 243 98 273 Volume
0.00% +0.62% -3.68% +3.18% +0.62% Change
More quotes
Company
Pulmatrix, Inc. is a clinical stage biotechnology company, which is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs.It designs and develops inhaled therapeutic... 
More about the company
Latest news on PULMATRIX INC
11/14 PULMATRIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
11/09 PULMATRIX : Management's Discussion and Analysis of Financial Condition and Resu..
11/09 PULMATRIX, INC. : Results of Operations and Financial Condition, Financial State..
11/09 PULMATRIX : Provides Q3 2017 Highlights and Q3 2017 Updated Financials
11/03 PULMATRIX, INC. : Entry into a Material Definitive Agreement, Other Events, Fina..
10/31 PULMATRIX : PULM) Appoints Dr. James Roach as CMO
10/30 PULMATRIX : Appoints Dr. James Roach as Chief Medical Officer
10/24 PULMATRIX INC : Pulmatrix: Company to Watch in Lung Disease Market
10/03 PULMATRIX : Antifungal Drug Candidate Receives a Second "Qualified Infectious Di..
09/28 PULMATRIX : to Present at the Cantor Fitzgerald Global Healthcare Conference on ..
More news
Sector news : Bio Therapeutic Drugs
09:31aDJBAYER : Amikacin Inhale Fails to Meet Objectives in Phase 3 Trial
11/22 U.S. FDA approves first two-drug HIV regimen in win for GSK
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
11/09 Pulmatrix reports Q3 results
10/03 Pulmatrix nabs second QIDP tag for Pulmazole; shares up 1%
09/20 Pulmatrix nabs two U.S. patents covering iSPERSE technology and PUR0200; shar..
09/19 After Hours Gainers / Losers
09/19 Pulmatrix CEO bullish on pipeline; shares ahead 9%
Chart PULMATRIX INC
Duration : Period :
Pulmatrix Inc Technical Analysis Chart | PULM | US74584P1030 | 4-Traders
Technical analysis trends PULMATRIX INC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Managers
NameTitle
Robert W. Clarke President, Chief Executive Officer & Director
Mark T. Iwicki Chairman
William E. Duke Chief Financial Officer, Treasurer & Secretary
David L. Hava Chief Scientific Officer
James M. Roach Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
PULMATRIX INC174.58%33
GILEAD SCIENCES1.69%95 098
REGENERON PHARMACEUTICALS5.57%41 637
VERTEX PHARMACEUTICALS99.59%37 187
GENMAB2.13%11 669
EXELIXIS, INC.75.25%7 731